Corey Goodman, Chairman of the Board
Dr. Corey Goodman is a scientist, educator, entrepreneur, and venture capitalist. He received his B.S. from Stanford University, his Ph.D. from U.C. Berkeley, and was a Helen Hay Whitney postdoctoral fellow at U.C. San Diego. He spent 25 years as Professor of Biology at Stanford University and Evan Rauch Chair of Neurobiology at Berkeley, where he was Howard Hughes Medical Institute Investigator, Head of the Neurobiology Division, and co-founder and Director of the Wills Neuroscience Institute. He is currently Adjunct Professor of Neuroscience at U.C. Berkeley.
Dr. Goodman is an elected member of the U.S. National Academy of Sciences, and recipient of many honors including the Alan T. Waterman Award, Canada Gairdner Biomedical Award, March-of-Dimes Prize, and Gruber Prize in Neuroscience.
Dr. Goodman co-founded seven biotechnology companies, and as CEO, took one of them (Renovis) from a private to public company until its acquisition by Evotec. He was recruited as President and founder of Pfizer's Biotherapeutics and Bioinnovation Center and a member of Pfizer's executive leadership team.
Today Dr. Goodman is a Managing Partner of venBio Partners, a venture capital firm he co-founded. In addition to MindRhythm, he is Chair of the Board of Second Genome, ALX Oncology (NASDAQ: ALXO), Tallac, Axonis, Attralus, and FogPharma. He is also a member of the Board of NFlection. He chaired Labrys Biologics, a company he founded, until its acquisition by Teva. The Labrys drug, now called Ajovy, is a CGRP antibody for chronic migraine that was approved by the FDA in 2018.
Pierre Lamond, Board Member
Pierre Lamond is a pioneer of the semiconductor industry. He started his career
in 1957 as an engineer at Transitron Electronics before joining Dr. Gordon E.
Moore’s R&D team at Fairchild Semiconductor. While at Fairchild, Pierre
oversaw the development of advanced high-frequency transistors and the first
generation of digital integrated circuits. Pierre left Fairchild in 1967 to cofound the National Semiconductor Corporation (NSM), where he was vice president and general manager, Integrated Circuits.
In 1981, Pierre joined Sequoia Capital as a general partner, where he played a
pivotal role in the expansion of the semiconductor, systems, and software
portfolios. While at Sequoia, Pierre was chairman of the board at Cypress
Semiconductor (CY), Microchip Semiconductor, Vitesse Semiconductor, Open-
Silicon Inc., Redback Networks, Verisity, and Plumtree.
Pierre left Sequoia in 2009 and joined Khosla Ventures in 2010. He spent four
years as a general partner at Khosla Ventures, serving on the boards of Skybox
Imaging (Google), Cogenra (SunPower), SEEO (Bosch), Avogy, SeaMicro
(AMD), and HeartVista. In 2015, he joined Eclipse Ventures where he served on the boards of Cerebras, Light, Flexlogix, SwiftNav and Oxide. Pierre left Eclipse in mid 2021. He now invests his own funds and focuses on seed investments in high technology and medical devices companies.
Franklin Berger, Board Member
Franklin Berger is a trusted analyst, and M&A advisor to biotech, med tech and therapeutic companies. Institutional Investor Magazine ranked Franklin #3 on the All-Star Research Team. The Wall Street Journal selected him as the No. 1 ranked biotechnology analyst in its All-Star Analyst Survey in 1997 and No. 2 ranked in the WSJ’s 2000 Survey. In 2024, he joined The Rockefeller University Incubator Selection Committee. He is a member of The Rockefeller University Council.
Franklin’s successful tenure began as a sell-side analyst at Josephthal & Co. in 1991, subsequently moving to Salomon Smith Barney in 1997 serving as Director, Equity Research and Senior Biotechnology Analyst. Franklin spent twelve years in sell-side equity research, most recently as Managing Director, U.S. Equity Research, at J.P. Morgan Securities, Inc. During his tenure at J.P. Morgan Securities, Inc., he was involved with the issuance of over $12 billion in biotechnology company equity or equity-linked securities. Trusting the value to future patients of specific technologies, he was and continues to be associated with several notable financings in the biotechnology sector including the Genentech IPO, then the largest biotechnology IPO financing ever executed, the first large Celgene Corporation financings as well as several large-cap biotechnology companies in their rapid growth phase. Most recently, Franklin acted as an essential participant in multiple notable acquisitions, specifically: Amgen’s acquisition of Five Prime for 1.9 billion in 2021, GlaxoSmithKline’s acquisition of Bellus Health for 1.9 billion in 2023, Cerus Endovascular acquired by Stryker for $525 million in 2023, and Atreca assets acquired by Immunome 2024 for an undisclosed price.
Franklin currently serves on the board of four public biotechnology companies: Atea Pharmaceuticals (NASDAQ:AVIR), ESSA Pharma (NASDAQ: EPIX), Satellos (TSX:MSCL) and Kezar Life Sciences (NASDAQ:KZR) as well as acting as Senior Advisor to Qiming Venture Partners, a position he has held since 2020.
John Keane, Co-Founder and CEO
John is a medical device executive with three decades of experience developing and commercializing emerging medical technologies. Having been involved in more than 30 product launches with a focus on neurological disorders, he brings a wealth of knowledge on product development, delivering clinical value and gaining adoption in the marketplace. As a strategic leader and advisor to multiple companies, John has proven success in defining vision and positioning companies for dynamic gains.
John sees beyond the status quo to identify and get to the heart of issues; stroke is a universal problem and John with his co-founders are focused on reducing time to treatment of Large Vessel Occlusion stroke by properly triaging patients in the prehospital setting.
“MindRhythm differentiates itself from anything else on the market. It provides a solution for a known problem, where nothing currently exists."
Paul Lovoi, PhD, Co-Founder and CTO
A serial entrepreneur, Paul has founded and funded eight companies in diverse fields including flat panel displays, laser paint stripping, oncology, cardiology, and stroke triage. With 43 years of experience inventing solutions to significant problems in technology and medicine, Paul is backed by a demonstrated track record of translating those solutions into the clinic. He is dedicated to guiding teams in new product development and working around solutions to make significant shifts in technology and markets.
Following the death of his wife due to a stroke, Paul was determined to prevent this from happening to others. In discovering the Headpulse algorithm, he found a way to accurately diagnose stroke in a non-invasive manner leading him to form MindRhythm.
“The device technology is a groundbreaking effect of the innovative product development and clinical proficiency from a team dedicated to lifesaving, diagnostic treatments. Seeing that solutions are made and brought into the marketplace in preventing stroke complications is at the utmost importance."
Wade Smith, MD, PhD, Co-Founder and Chair of the Scientific Advisory Board
Professor Smith is a Neurocritical care physician and the Chief of the Neurovascular Division at UCSF. The primary focus of his research career has been to develop novel treatments for stroke - specifically thrombectomy - and he is now innovating stroke triage to bring life-saving care to all citizens. Dr. Smith designed device prototypes and co-developed the artificial intelligence algorithms that form the foundation for MindRhythm's technology. Dr. Smith brings vast experience in stroke management as well as clinical trial design and FDA expertise. His clinical guidance will ensure that MindRhythm achieves its goal of reducing morbidity and mortality in stroke.
“We have the tools and manpower to treat the most serious form of ischemic stroke. However, in order to treat a patient, we have to get them from home or work to the closest hospital that can treat them because not all hospitals have these treatments. Currently, paramedics do not have the tools they need to make this decision. MindRhythm solves this problem by providing a novel, portable, inexpensive device that helps identify which stroke patient will benefit from these new treatments and locates the closest eligible hospital to treat them.”